Preeclampsia complicates approximately 8% of all pregnancies. A critical factor of outpatient monitoring is patient education; specifically, education regarding nature of the disease, ongoing short- and long-term risks, and warning signs and symptoms for worsening of disease. This study aims to compare patient knowledge using a novel illustration based app compared to standard discharge instructions.

Start Date01 May 2024

Sponsor / Collaborator

Memorial Health Services, Inc.

NCT05924971 / RecruitingPhase 2IIT

Acetylsalicylic Acid for Postpartum Preeclampsia: A Pilot Randomized Trial

The purpose of this research study is to evaluate the effect of low-dose aspirin on recovery from severe preeclampsia (a high blood pressure disorder of pregnancy) among women who have given birth. We hypothesize that taking aspirin for the first week after giving birth will enhance recovery from preeclampsia by decreasing the levels of a protein called soluble fms-like tyrosine kinase (sFlt-1), which is thought to be a main contributor to the development of preeclampsia, and speeding up return to a normal blood pressure.

Start Date26 Jul 2023

Sponsor / Collaborator

Memorial Health Services, Inc.

[+1]

NCT06363929 / RecruitingNot ApplicableIIT

A Study to Evaluate the Accuracy of Continuous Glucose Monitors in Neonates With Hyperinsulinism.

The investigators are studying the accuracy of Dexcom G6 continuous glucose monitors placed on babies with hyperinsulinism in the Miller Children's Hospital Neonatal Intensive Care Unit. The participants will wear the device for 10 days on their lateral thigh. Whenever blood sugars are checked by glucometer, the investigators will also record the continuous glucose monitor sugar. Additionally, if the continuous glucose monitor alarms for a low sugar or an impending low sugar, the investigators will check the blood sugar by glucometer and, if verified to be low, treat the low blood sugar accordingly.

Start Date01 Jun 2023

Sponsor / Collaborator

Memorial Health Services, Inc.

[+1]

100 Clinical Results associated with Memorial Health Services, Inc.

0 Patents (Medical) associated with Memorial Health Services, Inc.

750

Literatures (Medical) associated with Memorial Health Services, Inc.

01 Jun 2024·Journal of Pediatric Epilepsy

Standardizing the Treatment for Pediatric Status Epilepticus: A Quality Improvement Study

Author: Bhargava, Rishi ; Hestekin, Heather ; Cobo, Nicole ; Babbitt, Christopher ; Morphew, Tricia ; Smith, Gabrielle

AbstractApproximately 30 to 40% of children with generalized convulsive status epilepticus remain refractory to benzodiazepines. Due to inconsistences in our approach for these patients in the emergency department, we initiated a quality improvement project to standardize the treatment process.A plan, do, study, act (PDSA) format was used for the project that involved creating a treatment algorithm based on the American Epilepsy Society (AES) guidelines, educating the staff on the treatment recommendations, and then collecting clinical data. We selected time to second-line anticonvulsant therapy as our primary outcome measure. Following the implementation of the treatment algorithm and order set, we performed comparative analyses of the pre- and post-implementation cohorts.A total of 21 pre- and 36 post-implementation patients were identified. Baseline data demonstrated no difference in age or gender. Post-implementation patients received second-line therapy sooner (24 vs. 39 minutes, p = 0.001) and more post patients received second-line therapy within the AES guideline's time frame (83 vs. 52%, p = 0.012) compared with the pre-implementation patients. In a multivariable analysis, post-implementation patients had a higher likelihood of receiving second-line therapy within the AES-recommended time frame (odds ratio [OR] = 5.78; 95% confidence interval [CI]: 1.49–22.48; p = 0.011). Age, gender, intubation status, anticonvulsants given prior to emergency department (ED), and treatment by a pediatric ED specialist were not associated with increased odds of provider adherence to AES guidelines.In conclusion, a standardized approach utilizing a treatment algorithm for patients with pediatric benzodiazepine refractory status epilepticus was associated with reduced time to administration of second-line anticonvulsant therapy and better compliance with AES guidelines in a mixed pediatric and adult ED setting.

01 May 2024·American Journal of Obstetrics and Gynecology

Delivery outcomes in the subsequent pregnancy following the conservative management of placenta accreta spectrum disorder: a systematic review and meta-analysis

Review

Author: Carusi, Daniela A ; Shrivastava, Vineet K ; Silver, Robert M ; Duzyj, Christina M ; Hessami, Kamran ; Qaderi, Shohra ; Javinani, Ali ; Sandlin, Adam T ; Atasi, Lamia K ; Zuckerwise, Lisa C ; Lyell, Deirdre J ; Fox, Karin A ; Subramaniam, Akila ; Genc, Mehmet R ; Shainker, Scott A ; Kingdom, John C ; Bennett, Kelly A ; Mustafa, Hiba J ; Loftin, Ryan ; Shamshirsaz, Amir A ; Einerson, Brett D ; Khandelwal, Meena ; Newton, J M ; Carver, Alissa R ; Greiner, Andrea L ; Harrison, Rachel K ; Shamshirsaz, Alireza A ; Abdel-Razeq, Sonya S ; Gilner, Jennifer B

OBJECTIVECesarean hysterectomy is generally presumed to decrease maternal morbidity and mortality secondary to placenta accreta spectrum disorder. Recently, uterine-sparing techniques have been introduced in conservative management of placenta accreta spectrum disorder to preserve fertility and potentially reduce surgical complications. However, despite patients often expressing the intention for future conception, few data are available regarding the subsequent pregnancy outcomes after conservative management of placenta accreta spectrum disorder. Thus, we aimed to perform a systematic review and meta-analysis to assess these outcomes.DATA SOURCESPubMed, Scopus, and Web of Science databases were searched from inception to September 2022.STUDY ELIGIBILITY CRITERIAWe included all studies, with the exception of case studies, that reported the first subsequent pregnancy outcomes in individuals with a history of placenta accreta spectrum disorder who underwent any type of conservative management.METHODSThe R programming language with the "meta" package was used. The random-effects model and inverse variance method were used to pool the proportion of pregnancy outcomes.RESULTSWe identified 5 studies involving 1458 participants that were eligible for quantitative synthesis. The type of conservative management included placenta left in situ (n=1) and resection surgery (n=1), and was not reported in 3 studies. The rate of placenta accreta spectrum disorder recurrence in the subsequent pregnancy was 11.8% (95% confidence interval, 1.1-60.3; I²=86.4%), and 1.9% (95% confidence interval, 0.0-34.1; I²=82.4%) of participants underwent cesarean hysterectomy. Postpartum hemorrhage occurred in 10.3% (95% confidence interval, 0.3-81.4; I²=96.7%). A composite adverse maternal outcome was reported in 22.7% of participants (95% confidence interval, 0.0-99.4; I²=56.3%).CONCLUSIONFavorable pregnancy outcome is possible following successful conservation of the uterus in a placenta accreta spectrum disorder pregnancy. Approximately 1 out of 4 subsequent pregnancies following conservative management of placenta accreta spectrum disorder had considerable adverse maternal outcomes. Given such high incidence of adverse outcomes and morbidity, patient and provider preparation is vital when managing this population.

22 Mar 2024·Cancer Research

Abstract 4784: PATHFINDER 2: A prospective study to evaluate safety and performance of a multi-cancer early detection test in a population setting

Author: Kurbegov, Dax ; Richards, Donald ; Kim, Raymond H. ; Nabavizadeh, Nima ; Demeure, Michael J. ; Matrana, Marc ; Giridhar, Karthik V. ; Lopatin, Margarita ; Chen, Justin A. ; McDonnell, Charles ; Rybicki, Benjamin ; Stipec, Gretchen ; Matthews, Roland ; Gadgeel, Shirish

AbstractBackground: Multi-cancer early detection (MCED) tests are being established as a novel approach to screen for multiple cancer types with one test. A blood-based MCED test using cell-free DNA targeted methylation patterns to detect a shared cancer signal and predict a cancer signal origin (CSO) has demonstrated feasibility. An initial return of results study (PATHFINDER; NCT04241796) reported performance of a refined version of the MCED test, including a 43.1% positive predictive value (PPV), 98.5% negative predictive value (NPV), 99.5% specificity, and 88.0% CSO accuracy. To build on this work, the PATHFINDER 2 study (NCT05155605) will evaluate safety and performance of the MCED test in larger, more diverse populations.Methods: PATHFINDER 2 is a prospective, multicenter, interventional study. Participants ≥50 years of age will be enrolled, with specific targets to improve diversity (age, sex, race/ethnicity) and few exclusions due to comorbid conditions. Exclusion criteria include current clinical suspicion of cancer or recent cancer/treatment (within 3 years). Participants will undergo blood draw for MCED testing, followed by return of results (cancer signal detection and CSO) to the investigator and diagnostic evaluations if a cancer signal is detected. A confirmatory PET-CT scan will be performed when CSO-directed workups do not result in a cancer diagnosis. Participants will be followed for approximately 3 years. Primary endpoints include 1) MCED test safety in terms of diagnostic testing triggered by a positive result (number/type of procedures and adverse events) and 2) test performance (PPV, NPV, specificity, sensitivity, CSO accuracy, cancer detection rate and number needed to screen). Secondary endpoints include participant reported outcomes (eg, anxiety), utilization of guideline-recommended cancer screening, and cancer detection rate of confirmatory PET-CT, amongst others.The study plans to enroll approximately 35,000 participants across North America. Sites were selected based on geographic location, catchment area demographics, and practice setting (academic vs non-academic). Enrollment targets for age, sex and race/ethnicity (White [non-Hispanic] 72%; Hispanic or Latino 11%; African American or Black 11%; Asian, Native Hawaiian or Other Pacific Islander 6%; American Indian/Alaska Native 1%) were derived from US Census data. Strategies to promote diverse recruitment include translation of participant-facing documents across multiple languages, participant and healthcare provider educational material, and site-led community outreach campaigns.MCED testing is an emerging, potentially paradigm-changing strategy in cancer screening, and PATHFINDER 2 is designed to characterize the safety, performance, and clinical implementation of the MCED test as a screening tool in a broad and representative population.Citation Format: Karthik V. Giridhar, Michael J. Demeure, Raymond H. Kim, Justin A. Chen, Shirish Gadgeel, Dax Kurbegov, Margarita Lopatin, Roland Matthews, Marc Matrana, Charles McDonnell, Donald Richards, Benjamin Rybicki, Gretchen Stipec, Nima Nabavizadeh. PATHFINDER 2: A prospective study to evaluate safety and performance of a multi-cancer early detection test in a population setting [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4784.

News (Medical) associated with Memorial Health Services, Inc.

21 Oct 2024

·www.prnewswire.com

MemorialCare Saddleback Medical Center Unveils New Women's Health Pavilion with Ribbon Cutting Ceremony - Providing Specialized Care to Women in Orange County

LAGUNA HILLS, Calif., Oct. 21, 2024 /PRNewswire/ -- MemorialCare Saddleback Medical Center recently celebrated the grand opening of the Women's Health Pavilion – Orange County's first location that is completely dedicated entirely to women's health care at all stages of life – with a special ribbon cutting ceremony. The vision of the Women's Health Pavilion came not only from clinical leadership, but also women in the community, who provided valuable input on their needs during their health care journey. This one-stop-shop for women's health care needs provides a convenient place for women of all ages to receive preventive to specialty care in a safe and supportive space. Continue Reading MemorialCare Saddleback Medical Center held a ribbon cutting ceremony to officially announce the opening of its Women’s Health Pavilion. Attendees included MemorialCare executives, MemorialCare Board Members, and elected officials. "This all started with the vision of Dr. Gary Levine, who collaborated with our then Saddleback Medical Center Foundation board chair and retired OB-GYN, Dr. Cathy Han, both who have spent their careers as stewards of women's health," says Marcia Manker, CEO, MemorialCare Saddleback Medical Center. "Together, we knew we had a chance to do something special for this community. To provide a dedicated location with specialized women's health care unique to them." The Women's Health Pavilion spans three stories, each floor providing specialized care for women throughout every stage of their life. On the first floor is the comprehensive Sarah & Taylor Nederlander Breast Center, which spans over 20,000 square feet, making it one of the largest in the region with a serene, spa-inspired setting. In addition, it offers the most advanced technological capabilities for diagnosing breast cancer and osteoporosis, including 3D mammography, high-resolution ultrasounds, and the latest bone density screening on the market. The Nederlander Breast Center is known for its dedicated multidisciplinary team focused exclusively on breast health, including radiologists, surgeons, medical oncologists, and nurse navigators. "We are so grateful to Sarah and Taylor Nederlander," says Christy Ward, president, MemorialCare Saddleback Medical Center Foundation. "Because of their generous support, along with many others, this vision to provide elevated health care to women in one location has become a reality. We are honored to celebrate with our community, which has come alongside us to create this beautiful Women's Health Pavilion and the Sarah & Taylor Nederlander Breast Center for women in Orange County." Should the need arise, the Women's Health Pavilion's innovative approach extends to its second floor, where women have access to specialty women's cancer care under the guidance of distinguished oncologists and surgeons – Dr. Amy Bremner, medical director of breast surgical oncology; Dr. Bhavana Pathak, medical director of integrative oncology; Dr. Priyal Dholakiya, medical director of gynecologic oncology; Dr. Shawndeep Tung, breast oncologist; and Dr. Justin West, a new breast reconstruction surgeon who will be joining the team in November. This team brings expertise, empathy, and a holistic approach to cancer care, addressing patients' physical and emotional needs while focusing on leading clinical outcomes. Along with the dedicated cancer care, on the second floor is the Renewal Boutique, a cancer care boutique offering products to help women look and feel their best during and after cancer treatment. It is a valuable resource, specializing in quality products along with a team of certified fitters to ensure proper product fitting of post-mastectomy camisoles, swimwear and swim prostheses, leisure bras, light compression bras, silicone breast forms, wigs, and post-mastectomy bras. The team at Renewal Boutique is highly knowledgeable and can provide the right products for each woman, always recognizing the importance of privacy and dignity. Women's health and wellness begins with education. The Community Education Center and patio, located on the second floor, is dedicated to supporting patients through health classes, yoga classes including sessions specifically for cancer patients, cancer support groups, and education and support groups for new mothers. Any woman who gives birth at the Women's Hospital at MemorialCare Saddleback Medical Center will be provided with a complimentary postpartum class taught in the Community Education Center. On the third floor of the Women's Health Pavilion, patients have access to an expert team of obstetric and gynecologic physicians and certified nurse midwives who provide compassionate, evidence-based care for all stages of life with a personalized approach to ensure every woman is treated as if she is the only patient. This specialized care is provided by Dr. Rachael Lopez, OBGYN; Dr. Daniel Sternfeld, OBGYN; and Dr. Vaya Tanamai, OBGYN, including certified nurse midwives Denise Castellanos, Julie Vivalda, and Bonnie Martin. After the ribbon-cutting, guests went on a self-guided tour through the Pavilion where various activations were waiting for them. They had the opportunity to take a yoga class accompanied by a soothing candlelit sound bath, create a vision board to set goals for their future, visit a tea blending station where they made their own tea blend, and could also participate in a personalized breast cancer risk assessment. The Sarah & Taylor Nederlander Breast Center is open Monday to Friday 7 a.m. to 5 p.m. and on Saturday from 7 a.m. to noon. The other offices in the Women's Health Pavilion are open Monday to Friday from 9 a.m. to 5 p.m. Patients can make appointments by calling (949) 452-7200. The Women's Health Pavilion is conveniently located on the campus of MemorialCare Saddleback Medical Center, directly across from the main entrance of the hospital. For more information, visit memorialcare.org/whp. SOURCE MemorialCare Saddleback Medical Center WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

02 Oct 2024

·www.prnewswire.com

MemorialCare's Two Long Beach Hospitals Receive ABRET LAB-EEG Accreditations for Exceptional Brain Activity Testing

LONG BEACH, Calif., Oct. 2, 2024 /PRNewswire/ -- ABRET – a non-profit credentialing board globally advancing excellence in neurodiagnostics through accreditation and credentialing – recently accredited both MemorialCare Miller Children's & Women's Hospital Long Beach's Neurology Center and MemorialCare Long Beach Medical Center with a five-year electroencephalogram (EEG) accreditation called the LAB-EEG Accreditation. An EEG is a test detecting the brain's electrical activity and is used for diagnosing brain disorders like epilepsy, assessing seizures, monitoring brain function – especially during surgery – and advancing understanding of the brain. MemorialCare Long Beach Medical Center and MemorialCare Miller Children's & Women's Hospital are among only 18 out of 355 hospitals in California to receive this accreditation. They are also two of just seven hospitals with this accreditation in the Los Angeles and Orange County area. "It is an honor to receive this accreditation from ABRET," says Todd Blake, chief operations officer, MemorialCare Long Beach Medical Center and MemorialCare Miller Children's & Women's Hospital. "This accreditation is a testament to the dedicated work our EEG lab technologists do every day, and I am proud that our two hospitals are among the few hospitals within California with the ABRET accreditation. This is the expectation we set for ourselves so we can be at our best for our patients when they need us most." Patients looking for quality neurodiagnostic testing can be confident in hospitals with the LAB-EEG Accreditation since this accreditation confirms the lab's high reputation in quality outputs and patient care. Other benefits of receiving these accreditations include confirmation that the lab can produce EEGs interpretable by competent physicians anywhere, enhanced credibility when data is sent outside the institution, and being distinguished from local and regional competitors. ABRET Neurodiagnostic Credentialing and Accreditation is recognized worldwide as the premier credentialing board for Neurodiagnostic Professionals. The LAB-EEG accreditation is also recognized among the criteria used by the US News & World Report's Best Children's Hospitals to assess pediatric neurology and neurosurgery programs. Long Beach Medical Center and Miller Children's & Women's Hospital Long Beach receiving this accreditation shows their commitment to excellence in neurological diagnostics for all ages. Receiving their accreditations highlights their ability to cross-train and cover both pediatric and adult populations; this capability sets both hospitals apart from others. "ABRET's LAB-EEG program evaluates technical standards, lab policies and procedures, technologist credentialing and continued education, and the overall quality of the laboratory's EEG test output," says Cheryl Plummer, president, ABRET. "Successful accreditation means the EEG Laboratory has met strict standards and is to be recognized as a place where patients and physicians can have confidence in receiving quality EEG testing." About MemorialCare Long Beach Medical Center and MemorialCare Miller Children's & Women's Hospital Long Beach: MemorialCare's Long Beach Medical Center and Miller Children's & Women's Hospital Long Beach are members of MemorialCare, a not-for-profit, integrated healthcare delivery System. Long Beach Medical Center and Miller Children's & Women's are designated with the prestigious Magnet® recognition for excellence in nursing. Long Beach Medical Center, with a century of compassionate care across a spectrum of medical and surgical specialties, utilizes cutting-edge technology. Miller Children's & Women's provides specialized pediatric care for children and young adults — as well as maternity care for expectant mothers — all under one roof. Their shared campus ensures seamless care for patients of all ages, from newborns to older adults. Visit memorialcare.org/LongBeach and millerchildrens.org for more information. SOURCE MemorialCare's Long Beach Medical Center and Miller Children's & Women's Hospital Long Beach WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

18 Sep 2024

·www.prnewswire.com

Dr. Linda Chan Named Endowed Chair at MemorialCare Saddleback Medical Center

LAGUNA HILLS, Calif., Sept. 18, 2024 /PRNewswire/ -- MemorialCare Saddleback Medical Center has announced its inaugural Foundation Endowed Chair, Dr. Linda Chan, medical director of radiation oncology at MemorialCare Cancer Institute at Saddleback Medical Center. The MemorialCare Saddleback Medical Center Foundation has established the Endowed Chair Program as an important milestone in the 50-year history of the hospital, increasing the impact of philanthropy to positively impact patient care. Continue Reading MemorialCare Saddleback Medical Center has announced its inaugural Foundation Endowed Chair, Dr. Linda Chan, medical director of radiation oncology at MemorialCare Cancer Institute at Saddleback Medical Center. Endowed chairs are typically named for a single donor family, but this Foundation Endowed Chair represents the impact of thousands of Foundation donors over 50 years, and the earnings from this $1 million endowment will empower the chair holder to develop dynamic, hospital-based programs that benefit patients. "We are immensely proud to honor Dr. Chan as the inaugural Foundation Endowed Chair in recognition of her exemplary achievements and dedication to advancing medical excellence," says Christy Ward, president, MemorialCare Saddleback Medical Center Foundation. "As we celebrate this momentous occasion, it reinforces the power of donors to fuel innovation, education, and the well-being of our community." Dr. Chan, in partnership with program leaders, will use the Foundation Endowed Chair funds to invest in revolutionary technology and clinical program expansion, and provide education to patients within the south Orange County community to ensure a healthier future. "Dr. Chan has always been dedicated to identifying the best, most effective treatments of cancer," says Marcia Manker, CEO, MemorialCare Saddleback Medical Center. "While she is a phenomenal radiation oncologist, her work in cancer research transcends programmatic growth and development and is deeply tied to our mission. In addition, her commitment to excellence as a physician partner allows us to collectively focus on providing high-quality, compassionate care to the community we serve." On Sept. 17 the Foundation hosted an Investiture Ceremony, with physicians formally processing in together in their white coats, to recognize Dr. Linda Chan as the chair holder. White coat ceremonies are typically reserved as a rite of passage that marks the transition of medical students into the clinical phase of their studies and the medical profession. For Dr. Chan, this white coat ceremony honored her work and dedication to providing exceptional care to the community. "I am so honored and humbled to be recognized by the Saddleback Medical Center Foundation Board of Directors, our executive leadership team, and my colleagues," says Linda Chan, M.D., medical director, Radiation Oncology, Saddleback Medical Center. "This Endowment emphasizes the commitment of our Board and our leadership to advancing personalized cancer care. The funds will support innovative research challenging established dogma in our quest for optimal cancer care. I appreciate that Saddleback Medical Center wants to take the next step forward in transformational medicine." Originally from Orange County, Dr. Chan obtained her medical doctorate from Harvard Medical School. She did research at the National Institutes of Health (NIH) Department of Radiation Oncology, under an NIH Cancer Research Fellowship and Grunebaum Cancer Fellowship. Dr. Chan has authored multiple scientific publications on breast cancer, prostate cancer, and the molecular markers used to diagnose and track cancer. She also works on several committees of national health care policy, both through the American Society of Radiation Oncologists and the American College of Radiology. About Saddleback Medical Center Foundation Saddleback Medical Center Foundation, a 501(c)(3) nonprofit organization, raises philanthropic support for MemorialCare Saddleback Medical Center, a community-based, nonprofit hospital. The generous support of donors enables Saddleback Medical Center Foundation to support the medical center's leading edge health care, technology and medical expertise, as well as provide programs and services for the community. To learn more about supporting Saddleback Medical Center through the Foundation, please call (949) 452-3724 or go to memorialcare.org/smcf. About MemorialCare Saddleback Medical Center MemorialCare Saddleback Medical Center is a member of MemorialCare, a not-for-profit, integrated healthcare delivery system – proudly serving the residents of South Orange County for 50 years. Centers of Excellence include cancer, heart, orthopedics, spine, neurosciences, gastroenterology, emergency and critical care, breast health, imaging, women's health, obstetrics, geriatrics, and minimally invasive and robotic-assisted surgery. Saddleback Medical Center received U.S. News & World Report high-performance rankings for cardiology, diabetes, knee replacement, and stroke to name a few. It also was named among Healthgrades America's 250 Best Hospitals, Top 50 U.S. Cardiovascular Hospitals and received Magnet Nursing Excellence designation. In addition, it is a certified geriatric ED Thrombectomy-Capable Stroke Center and holds Geriatric Emergency Department Accreditation. Currently, Saddleback is building the first of its kind Women's Health pavilion bringing women's specialty care under one roof, set to open in Fall 2024. To learn more, visit memorialcare.org/saddleback. SOURCE MemorialCare Saddleback Medical Center WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Radiation Therapy

100 Deals associated with Memorial Health Services, Inc.

100 Translational Medicine associated with Memorial Health Services, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 Dec 2024

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Memorial Health Services, Inc.

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 23 Dec 2024

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing